Senior Regulatory Affairs Executive
4 Years of Experience Medical device regulatory professional specializing in EU MDR 2017/745
Overview of BfArM Vigilance in Germany
The BfArM Vigilance Reporting Process is the mandatory legal procedure for reporting serious medical device incidents, safety risks, and Field Safety Corrective Actions (FSCAs) to Germany’s Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte). Governed by Articles 87–92 of the European Medical Device Regulation (EU MDR 2017/745) and Germany’s Medical Devices Implementation Act (MPDG), this system protects patients and users by ensuring rapid risk mitigation across the German market.
For manufacturers, Authorized Representatives, and importers placing devices on the German market, mastering post-market reporting is essential to maintaining market access. This guide details the step-by-step BfArM Vigilance Reporting Process, mandatory Manufacturer’s Incident Report (MIR) form v7.3.1 updates, strict statutory timelines, and audit-ready documentation practices.
What is BfArM?
The Federal Institute for Drugs and Medical Devices (BfArM)—Bundesinstitut für Arzneimittel und Medizinprodukte—is Germany’s federal authority responsible for overseeing the safety, risk assessment, and post-market monitoring of medical devices. (High-risk in vitro diagnostics and tissue-based products fall under the Paul-Ehrlich-Institut.)
How Does BfArM Vigilance Work?
BfArM vigilance is the statutory post-market safety monitoring and reporting system enforced in Germany to identify, assess, andBfArM Vigilance is the national safety reporting framework used to collect, investigate, and respond to serious device incidents. Because the EU’s central EUDAMED vigilance module is still transitioning toward full mandatory operation, manufacturers and their Authorized Representative for Medical Devices in Germany must report vigilance events directly to BfArM. When a device failure traces back to a design flaw or material defect, regulatory reviewers often cross-examine vigilance findings against your Design History File (DHF) documentation to verify whether foreseeable risks were adequately controlled prior to market release. mitigate medical device incidents and adverse events. It ensures that manufacturers, importers, and authorized representatives detect device risks early and execute timely corrective measures.
Mandated under both European Union Medical Device Regulation (EU) 2017/745 (MDR) and German national legislation (MPDG), BfArM vigilance reporting legally obligates manufacturers to report safety concerns promptly. Establishing compliant quality and post-market frameworks from day one helps companies prevent regulatory disruptions during market entry and routine surveillance audits.
Which Incidents Must Be Reported to BfArM?
Not every customer complaint requires a competent authority filing, so distinguishing routine feedback from mandatory vigilance triggers is essential. Under EU MDR Article 87, you must initiate the BfArM Vigilance Reporting Process for:
Serious Incidents: Any device malfunction, deterioration in characteristics or performance, or inadequacy in the Instructions for Use (IFU) that directly or indirectly led—or could have led—to a patient’s death or a serious deterioration in health (such as life-threatening illness, permanent impairment, or surgical intervention).
Near-Miss Events: Device errors that did not result in patient harm solely because of fortunate circumstances or timely clinical intervention, but carry the risk of causing serious harm if they happen again.
Field Safety Corrective Actions (FSCAs): Any recall, device exchange, software update, or labeling revision undertaken to reduce the risk of serious harm for devices already distributed in Germany.
Significant Trend Increases: A statistically significant rise in the frequency or severity of non-serious incidents or expected side effects detected during ongoing post-market market intelligence and surveillance reviews.
For complex technologies—such as pre-filled syringes, drug-eluting stents, or smart inhalers—teams must also align incident reporting with drug-device combination product documentation rules, as medicinal and device vigilance pathways can overlap.
Unsure whether a recent field complaint meets BfArM’s serious incident threshold? Speak with Operon Strategist’s EU MDR specialists to evaluate reportability before your statutory clock runs out.
How the BfArM Vigilance Reporting Process Works (Step-by-Step)
When an adverse event occurs, manufacturers must move quickly through five interconnected stages:
Log the Awareness Date and Triage the Event The exact date any employee, distributor, or Authorized Representative first learns of a potentially reportable incident becomes your Manufacturer Awareness Date. Your legal countdown starts immediately on this day. Evaluate the event against EU MDR serious incident criteria (MDCG 2023-3); if doubt remains, file an initial report within the deadline rather than risking non-compliance.
Compile the Manufacturer’s Incident Report (MIR Form v7.3.1) Document the event using the European Commission’s standardized MIR form version 7.3.1 (mandatory across the EU since May 1, 2026). Include the device’s Basic UDI-DI and UDI-PI, batch/serial numbers, clinical event narrative, IMDRF Annex codes, preliminary root-cause analysis, and whether the filing is an Initial, Follow-up, Combined Initial & Final, or Final report.
Transmit the Filing Before BfArM’s Statutory Deadline Send the completed MIR XML/PDF package electronically to BfArM (
md-vigilance@bfarm.de). EU MDR enforces strict calendar-day limits based on severity:Serious Public Health Threat: Immediately, and no later than 2 calendar days after awareness.
Death or Unanticipated Serious Deterioration in Health: Immediately, and no later than 10 calendar days after awareness.
All Other Serious Incidents: Immediately, and no later than 15 calendar days after awareness.
Field Safety Corrective Action (FSCA): Prior to implementing the action, unless an immediate threat requires urgent field intervention.
Execute Field Safety Corrective Actions and Issue a German FSN If your investigation reveals an ongoing hazard in distributed stock, submit an FSCA notification to BfArM and distribute a clear Field Safety Notice (FSN) translated into German to affected hospitals, clinicians, and distributors. Track customer acknowledgments to prove effective communication. Where corrective actions require hardware redesign or assembly line adjustments, integrating product and process engineering for manufacturing helps prevent recurrence at the production source.
Update Risk Files, CAPA, and Post-Market Surveillance Records Link every vigilance report to your Corrective and Preventive Action (CAPA) log, ISO 14971 Risk Management File, and Periodic Safety Update Report (PSUR). Maintaining this closed-loop traceability is essential during Notified Body surveillance audits and complements the foundational steps covered in our Medical Device Registration in Germany: Step-by-Step CE Marking Guide.
Why Timely BfArM Compliance Protects Your German Market Access
Treating vigilance as a proactive engineering and quality discipline—rather than a reactive paperwork exercise—delivers measurable operational benefits. Prompt reporting stops defective batches from causing widespread patient harm, prevents heavy administrative fines or forced market withdrawals under German MPDG enforcement, and demonstrates robust post-market control during Notified Body audits.
End-to-End German Vigilance & Post-Market Support by Operon Strategist
Managing adverse event investigations across language barriers and strict EU MDR timelines can strain internal quality teams. Operon Strategist helps medical device manufacturers build and run compliant German vigilance operations through:
Vigilance SOP & Awareness-Clock Workflows: Designing audit-ready post-market reporting procedures within your ISO 13485 Quality Management System (QMS), aligned with EU MDR Articles 87–92 and German MPDG rules.
MIR Form v7.3.1 Review & Submission Support: Auditing UDI data, IMDRF coding, and root-cause narratives to ensure accurate initial, follow-up, and final filings under ongoing EU MDR and IVDR CE marking compliance.
FSCA Strategy & German FSN Drafting: Structuring corrective action plans, preparing compliant Field Safety Notices, and tracking distributor and hospital responses.
CAPA, PSUR & Risk File Integration: Connecting post-market incident trends back into your Risk Management File, Periodic Safety Update Reports, and medical device clinical evaluation services for seamless Notified Body inspections.
Talk to Operon Strategist’s regulatory experts today
FAQ's
What is BfArM Vigilance?
BfArM Vigilance is Germany’s mandatory post-market safety monitoring system managed by the Federal Institute for Drugs and Medical Devices to track, evaluate, and respond to medical device incidents and corrective actions.
What types of incidents must be reported to BfArM?
Manufacturers must report any serious incident causing death or serious health deterioration, device malfunctions that could cause serious harm if they recur, and any Field Safety Corrective Action (FSCA).
What are the deadlines for submitting an incident report to BfArM?
Under EU MDR, reports must be submitted within 2 days for a serious public health threat, within 10 days for death or unanticipated serious health deterioration, and within 15 days for other serious incidents.
What form is used to submit an incident to BfArM?
Manufacturers use the standardized European Manufacturer’s Incident Report (MIR) form submitted electronically to BfArM.
What happens if a manufacturer fails to comply with BfArM Vigilance?
Non-compliance can result in regulatory sanctions, financial penalties, mandatory product recalls, or suspension of market access in Germany and the European Union.
Senior Regulatory Affairs Executive | 4 Years of Experience
Medical device regulatory professional specializing in EU MDR 2017/745 technical documentation, CE marking, risk management, clinical and biological evaluation, and post-market surveillance. His expertise includes SFDA MDMA submissions, CDSCO licensing, ISO 13485, MDSAP, US FDA regulatory requirements, and BIS certification.


